buyModerate
G. Walmsley Graham bought $8.8M of AKRO
director at Akero Therapeutics, Inc.. 200,000 shares at an average of $43.94, traded Mar 25, 2025, filed Mar 27, 2025.
Conviction score
51Value
$8.8M
200,000 shares
Holdings after
1,200,000
+20% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$8.8M at market
- +6Relative to holdingsHoldings up 20%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-046271, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 25, 2025 | POpen-market purchase Common Stockindirect: See Footnote 1 | +91,309 | $44.75 | $4.1M | 1,091,309 | Mar 27, 2025 |
| Mar 26, 2025 | POpen-market purchase Common Stockindirect: See Footnote 1 | +58,691 | $43.01 | $2.5M | 1,150,000 | Mar 27, 2025 |
| Mar 27, 2025 | POpen-market purchase Common Stockindirect: See Footnote 1 | +50,000 | $43.55 | $2.2M | 1,200,000 | Mar 27, 2025 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 5Weak | Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $108k 2,000 shares | -6% | |
| 14Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $542k 10,000 shares | -10% | |
| 44Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $80k 1,453 shares | -1% | |
| 39Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $90k 1,633 shares | -2% | |
| 46Moderate | Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $90k 1,634 shares | -3% | |
| 37Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $62k 1,129 shares | -1% | |
| 37Weak | Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $48k 875 shares | -3% | |
| 36Weak | Akero Therapeutics, Inc. | Scott A. Gangloff Chief Technology Officer | $47k 848 shares | -3% | |
| 55Moderate | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $363k 6,620 shares | -1% | |
| 46Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $135k 2,493 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.